Cargando…

Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population

BACKGROUND: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia-Hao, Chen, Yen-Fu, Wu, Vin-Cent, Shu, Chin-Chung, Lee, Chih-Hsin, Wang, Jann-Yuan, Lee, Li-Na, Yu, Chong-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898246/
https://www.ncbi.nlm.nih.gov/pubmed/24410958
http://dx.doi.org/10.1186/1471-2334-14-23
_version_ 1782300390321029120
author Chang, Chia-Hao
Chen, Yen-Fu
Wu, Vin-Cent
Shu, Chin-Chung
Lee, Chih-Hsin
Wang, Jann-Yuan
Lee, Li-Na
Yu, Chong-Jen
author_facet Chang, Chia-Hao
Chen, Yen-Fu
Wu, Vin-Cent
Shu, Chin-Chung
Lee, Chih-Hsin
Wang, Jann-Yuan
Lee, Li-Na
Yu, Chong-Jen
author_sort Chang, Chia-Hao
collection PubMed
description BACKGROUND: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery. METHODS: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis. RESULTS: Ninety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1–180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin. CONCLUSIONS: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.
format Online
Article
Text
id pubmed-3898246
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38982462014-01-23 Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population Chang, Chia-Hao Chen, Yen-Fu Wu, Vin-Cent Shu, Chin-Chung Lee, Chih-Hsin Wang, Jann-Yuan Lee, Li-Na Yu, Chong-Jen BMC Infect Dis Research Article BACKGROUND: Patients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery. METHODS: From 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis. RESULTS: Ninety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1–180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin. CONCLUSIONS: Renal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI. BioMed Central 2014-01-13 /pmc/articles/PMC3898246/ /pubmed/24410958 http://dx.doi.org/10.1186/1471-2334-14-23 Text en Copyright © 2014 Chang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chang, Chia-Hao
Chen, Yen-Fu
Wu, Vin-Cent
Shu, Chin-Chung
Lee, Chih-Hsin
Wang, Jann-Yuan
Lee, Li-Na
Yu, Chong-Jen
Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title_full Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title_fullStr Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title_full_unstemmed Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title_short Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
title_sort acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898246/
https://www.ncbi.nlm.nih.gov/pubmed/24410958
http://dx.doi.org/10.1186/1471-2334-14-23
work_keys_str_mv AT changchiahao acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT chenyenfu acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT wuvincent acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT shuchinchung acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT leechihhsin acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT wangjannyuan acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT leelina acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation
AT yuchongjen acutekidneyinjuryduetoantituberculosisdrugsafiveyearexperienceinanagingpopulation